drugset / Trial / NCT00649610

Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain

NCT00649610

Phase 4 Completed 340 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The pain relief, safety, and tolerability of valdecoxib 40 mg once daily compared with diclofenac 75 mg twice daily for acute low back pain was studied. The effect of valdecoxib on the patient's level of disability and quality of life was also studied.

Timeline

Start
2002-11
Primary completion
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diclofenac Other / unclassified 75 mg
Comparator valdecoxib Small molecule 40 mg

Indications

No indication recorded.